Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks

Unregulated peptide use is emerging as a digitally mediated public health concern. Although peptide-based medicines have important therapeutic roles when developed, prescribed, manufactured, and monitored through regulated pathways, online biohacking and wellness spaces increasingly promote experimental or weakly evidenced peptides for fat loss, recovery, aesthetics, cognition, performance, and longevity. This narrative review examines how digital promotion, gray-market access, self-injection, stacking, informal titration, product-quality uncertainty, regulatory ambiguity, and weak pharmacovigilance interact to normalize poorly traceable peptide products outside clinical supervision. The central concern is not legitimate peptide medicine, but consumer experimentation with products of uncertain identity, purity, potency, sterility, and safety. Improved clinician awareness, adverse-event reporting, product-quality monitoring, digital risk communication, and proportionate regulatory oversight are needed to distinguish evidence-based peptide therapy from unregulated consumer use.